#Canada #Calgary #Innocan Pharma #Osteoarthritis #Liposomal CBD

Breakthrough Pain Relief for Donkeys

In recent developments in veterinary medicine, Innocan Pharma Corporation has unveiled remarkable results from their liposomal CBD injection, specifically designed for pain relief. This innovative treatment showcased its efficacy through a compassionate trial involving an elderly female donkey named Ariel, who had been suffering from osteoarthritis. At 35 years old, Ariel faced chronic pain and mobility issues due to years of excessive weight-bearing activities.

The Treatment Journey

Ariel’s rehabilitation commenced when she received a single dose of Innocan's liposomal CBD injection (LPT-CBD). Notably, the treatment provided immediate and lasting relief, helping Ariel regain her mobility for several weeks. The success of this initial application led to a subsequent injection, which yielded even further improvements in her condition, underscoring the potential of LPT-CBD in veterinary healthcare.

Prof. Chezy Barenholz, head of Innocan’s Scientific Advisory Board, elaborated on this significant breakthrough, stating, “Once again, Innocan's Liposomal CBD demonstrates its strong potential and effectiveness in alleviating pain and enhancing well-being in animals.” The positive outcomes observed in this second donkey treatment added to previous experiments conducted on other large animals, reinforcing the notion that LPT-CBD is viable for diverse veterinary applications.

Implications for Veterinary Medicine

The implications of this treatment are profound. The quick and prolonged relief administered to Ariel not only showcases an effective method for managing chronic pain in large animals but also opens doors for further research in veterinary medicine, particularly for species such as ruminants and pigs. Inncoan's innovation prompts a significant shift towards alternatives for pain management that can benefit non-human patients remarkably.

Future Human Trials

Moreover, this novel treatment transcends veterinary applications. Innocan has successfully completed a preliminary meeting with the FDA, gearing towards exploring LPT-CBD as a non-opioid alternative for chronic pain relief in humans. Dr. Eyal Kalo, Innocan's RD Director, stated, “The prolonged pain relief experienced by the donkey adds to a growing body of evidence suggesting the potential of LPT-CBD for human pain management.” This dual applicability marks a significant evolution in how CBD-based therapies are perceived and their future utilization in both veterinary and human medicine.

About Innocan Pharma

Innocan Pharma stands at the forefront of innovation within the pharmaceutical and wellness sectors. Their liposomal CBD drug delivery platform ensures accurate dosing with a focus on prolonged and controlled release for effective pain management. Apart from their veterinary advancements, Innocan continues to explore and market a range of wellness products aimed at promoting healthier lifestyles through their subsidiary, BI Sky Global Ltd.

In conclusion, Innocan Pharma’s groundbreaking approach in utilizing liposomal CBD for the treatment of osteoarthritis in an elderly donkey symbolizes a promising step forward in both veterinary and human healthcare. As researchers and medical professionals anticipate further studies and trials, the potential for LPT-CBD to revolutionize pain management is becoming increasingly apparent.

For more information about Innocan Pharma and their innovative products, visit Innocan Pharma.